Abstract
Invasive pulmonary aspergillosis (IPA) is a leading cause of morbididy and mortality for patients with malignancy and transplantation recipients. Recent advances in diagnosis and treatment strategies can improve patients' survival. In addition, because the epidemiologies of invasive fungal infections would differ between Korea and Western countries, Organization of a nationwide network in collaboration with infectious diseases specialists, medical microbiologists, and government personnels is also anticipated. Due to a restricted reimbursement system in Korea, current clinical practices for treatment of IPA are limited. According to the textbooks and guidelines from results of well designed clinical trials and extensive clinical experiences, criteria for insurance benefits should be improved in the near future.
| Original language | English |
|---|---|
| Pages (from-to) | 328-330 |
| Number of pages | 3 |
| Journal | Infection and Chemotherapy |
| Volume | 44 |
| Issue number | 4 |
| DOIs | |
| State | Published - Aug 2012 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Epidemiology
- Health
- Insurance
- Invasive pulmonary aspergillosis
- Reimbursement
Fingerprint
Dive into the research topics of 'Epidemiology and clinical characteristics of invasive pulmonary aspergillosis in Korea: Tasks for the future'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver